Search

EP-4734974-A1 - CANNABINOID COMPOSITION FOR USE IN THE TREATMENT OF PAIN AND/OR INFLAMMATION

EP4734974A1EP 4734974 A1EP4734974 A1EP 4734974A1EP-4734974-A1

Abstract

The present invention relates to a composition for use in the treatment of pain and/or an inflammatory disease. Said composition comprises a first component and a second component in a weight ratio of the first component to the second component of between 0.5 to 0.9, the first component being selected from tetrahydrocannabivarin (THCV), tetrahydrocannabivarin acid (THCVA) and mixtures thereof, and the second component being selected from tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA) and mixtures thereof.

Inventors

  • GALL, STEFAN
  • HALLE, Christian
  • Gertsch, Jürg

Assignees

  • Mabewo Phytopharm AG

Dates

Publication Date
20260506
Application Date
20240701

Claims (20)

  1. 1. A composition for use in the treatment of pain and/or an inflammatory disease, wherein said composition comprises a first component and a second component in a weight ratio of the first component to the second component of between 0.5 to 0.9, the first component being selected from tetrahydrocannabivarin (THCV), tetrahydrocan- nabivarin acid (THCVA) and mixtures thereof, and the second component being selected from tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA) and mixtures thereof.
  2. 2. The composition for use according to claim 1 , wherein the first component is THCV and the second component is THC.
  3. 3. The composition for use according to claim 1 or 2, wherein the weight ratio is in a range from 0.6 to 0.8.
  4. 4. The composition for use according to any one of claim 1 to 3, wherein the weight ratio is 0.8.
  5. 5. The composition for use according to any one of claims 1 to 4, wherein the composition is free of curcuminoids.
  6. 6. The composition for use according to any one of claims 1 to 5, wherein the pain is selected from neuropathic pain, inflammatory pain, postoperative pain, cancer-related pain, pelvic pain, bone pain, abdominal pain, joint pain, visceral pain, muscle pain, and headache.
  7. 7. The composition for use according to any one of claims 1 to 5, wherein the inflammatory disease is selected from skin inflammation, rheumathoid arthritis, osteoarthritis, articular inflammation, periarticular inflammation, non-articular rheumatism, capsulitis, tendonitis, and fibrositis.
  8. 8. The composition for use according to any one of claims 1 to 7, wherein the composition further comprises one or more pharmaceutically acceptable excipients.
  9. 9. The composition for use according to any one of claims 1 to 8, wherein the composition is a solid composition, semi-solid composition or a liquid composition.
  10. 10. The composition for use according to any one of claims 1 to 9, wherein the first component and/or the second component are in synthetic form or isolated form.
  11. 11. The composition for use according to any one of claims 1 to 10, wherein the composition does not contain further cannabinoids.
  12. 12. The composition for use according to any one of claims 1 to 9, wherein the composition is in the form of a plant extract.
  13. 13. The composition according to claim 12, wherein the plant extract is a cannabis plant extract.
  14. 14. The composition according claim 13, wherein the cannabis plant extract is a Cannabis sativa L. flos extract.
  15. 15. The composition according to claim 10 comprising • the second component in the form of a cannabis plant extract comprising between 5% (w/w) to 35% (w/w) of the second component and being essentially free of the first component, and • the first component being in synthetic or isolated form.
  16. 16. The composition according to claim 15, wherein the cannabis plant extract comprises between 25% (w/w) to 30% (w/w) of the second component.
  17. 17. The composition according to claim 15 or 16, wherein the cannabis plant extract is a Cannabis sativa L. flos extract.
  18. 18. The composition according to any one of claims 1 to 17, wherein the composition is essentially free of cannabidiolic acid and cannabidiol.
  19. 19. The composition for use according to any one of claims 1 to 18 in combination with one or more non-cannabinoid medicinal substances, preferably selected from opioids, steroidal and non-steroidal anti-inflammatory drugs, and triptans.
  20. 20. The composition for use according to claim 19, wherein opioids are selected from tramadol, oxycodone, fentanyl, methadone, dextromethorphan, meperidine, codeine, and buprenorphine; non-steroidal anti-inflammatory drugs are selected from ibuprofen, paracetamol, diclofenac, acetylsalicylic acid, metamizole, naproxen, and indomethacin; triptans are selected from sumatriptan, rizatriptan, naratriptan, eletriptan, do- nitriptan, almotriptan, frovatriptan, avitriptan, and zolmitriptan; steroidal anti-inflammatory drugs are selected from hydrocortisone, cortisone, prednisolone, methylprednisolone, beclomethasone, and dexamethasone.

Description

CANNABINOID COMPOSITION FOR USE IN THE TREATMENT OF PAIN AND/OR INFLAMMATION TECHNICAL FIELD The present invention relates to a cannabinoid composition for use in the treatment of pain and/or an inflammatory disease. BACKGROUND Pain and inflammation are two of the most frequent reasons to seek medical consultation, often severly impacting the quality of life of patients. Accordingly, health-care expenditures for pain and inflammatory diseases are high, let alone the economic costs associated with these conditions. However, the pathophysiology of both conditions is often complex and thus challenging to adequately address. Further, while pain and inflammation are often interrelated, e.g., pain being a symptom of an inflammatory disease (also sometimes referred to as inflammatory pain), treatment options for both conditions typically differ. Pain: Pain is often classified into nociceptive pain, neuropathic pain, and psychogenic pain. In addition, pain may occur suddenly, also referred to as acute pain, which is often caused by injury, surgery, illness, trauma, or painful medical procedures. Acute pain generally lasts from a few minutes to less than six months. However, pain may also persist for longer periods of time, also referred to as chronic pain. Whereas acute pain can often be successfully managed with non-steroidal anti-inflammatory drugs (NSAIDs) and/or opioids, chronic pain is typically difficult to treat. In nociceptive pain, the stimulation of the sensory nerve endings called nociceptors cause the sensation of pain. Such pain often occurs after injury or surgery, also referred to as postoperative pain. Psychogenic pain is a pain disorder that is associated with psychological factors. Some types of mental or emotional problems can cause pain. The underlying cause of psychogenic pain is often difficult to detect and the diagnosis is made when no physical cause of pain could be identified. Nevertheless, people suffering from this disorder have real pain. In addition, psychological factors may also increase or prolong pain for which a physical cause could be identified. For example, psychological factors often have an impact on headache, muscle pain, back pain, and stomach pain. Neuropathic pain results from an injury or malfunction of the peripheral or the central nervous system. In addition, neuropathic pain is typically chronic and is often refractory to treatment with opioids. Neuropathic pain can be further classified into peripheral neuropathic pain and central neuropathic pain, depending on whether the peripheral or central nervous system is affected. For example, central neuropathic pain is often associated with spinal cord injury and multiple sclerosis. Examples of peripheral neuropathic pain include e.g., postherpetic neuralgia and allodynia. Postherpetic neuralgia results if nerve fibers get damaged during an outbreak of shingles. Allodynia, on the other hand, is characterized by a painful response to a typically non-painful stimulus, for example brushing the affected area with a fingertip. In allodynia, the pain tends to increase with repeated stimulation and may even spread from the affected area. In addition, allodynic pain can be evoked in response to chemical, thermal (cold or heat) or mechanical low or high intensity stimuli applied either statically or dynamically to skin, joints, bone, muscle or viscera. However, other classifications of pain are also possible, with frequent overlap. For example, pain may be classified by its location, e.g., pelvic pain, bone pain, abdominal pain, joint pain, visceral pain, muscle pain or headache. Headache can be further classified as migraine headache, tension headache, hypnic headache and cluster headache. In addition, pain may be classified according to an underlying condition, e.g. postoperative pain, cancer-related pain, inflammatory pain, endometriosis pain (causes pain in the pelvic region) and migraine headache (migraine headache being a sympotom of migraine). Inflammation: Inflammation is typically defined as a response of the body towards invading pathogens or endogenous signals such as damaged cells/tissue. Whereas inflammation is an important physiological response that can result in tissue repair and support the defense against pathogens, inflammation may become pathologic when the response goes unchecked. Inflammation is typically divided into acute inflammation and chronic inflammation. Acute inflammation typically relates to the response to sudden body damage, e.g. after an injury. In acute inflammation, the inflammatory cells play an important role to initiate the healing process. In chronic inflammation, release of inflammatory cells continues even when there is no physiological purpose. For example, in rheumatoid arthritis, inflammatory cells attack joint tissues, beginning with the lining of joint. Osteoarthritis, on the other hand, involves the wearing away of cartilage that caps the bones in the joints. Both inflammatory disea